<DOC>
	<DOCNO>NCT00616980</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy intramuscular injection adult stem cell patient Critical Limb Ischemia ( CLI ) .</brief_summary>
	<brief_title>Injection Autologous CD34-Positive Cells Critical Limb Ischemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>2180 year age moderate highrisk Critical Limb Ischemia ( Rutherford Clinical Severity Score 4 5 ) unsuitable conventional revascularization advance CLI ( Rutherford Clinical Severity Score 6 ) characterize extensive tissue loss gangrene advance AV block NYHA Class III Class IV heart failure myocardial infarction within 3 month treatment successful coronary low extremity revascularization within 3 month study enrollment arterial insufficiency lower extremity result nonatherosclerotic disorder exception thromboangitis obliterans ( Buerger 's Disease ) comorbidity associate life expectancy le 1 year</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>PAD</keyword>
	<keyword>PVD</keyword>
	<keyword>CLI</keyword>
	<keyword>Stem Cells</keyword>
</DOC>